![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer’s Bococizumab Yields Positive Results in Phase 3
Pfizer’s Bococizumab Yields Positive Results in Phase 3
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
April 7, 2016
Pfizer’s bococizumab soared in a second Phase 3 study, meeting its co-primary endpoints of reducing low-density lipoprotein cholesterol at 12 weeks compared with placebo.
The SPIRE-AI study assessed the PCSK9 inhibitor in 299 patients with hyperlipidemia or mixed dyslipidemia receiving statin therapy. SPIRE-AI is the second of six studies evaluating the candidate’s lipid-lowering capabilities.
Bococizumab is not approved in any country.
Upcoming Events
-
21Oct